Lercanidipine HydrochlorideThird Party Manufacturing in India

Lercanidipine hydrochloride is a dihydropyridine calcium channel blocker that exerts its antihypertensive effect by inhibiting the transmembrane influx of calcium ions into vascular smooth muscle cells and cardiac myocytes. It binds selectively to L-type calcium channels in the cell membrane, particularly those located in vascular smooth muscle, where it prevents the voltage-dependent entry of calcium during depolarization. This reduction in intracellular calcium concentration leads to relaxation of the vascular smooth muscle, resulting in peripheral vasodilation and a corresponding decrease in systemic vascular resistance. The drug exhibits high vascular selectivity compared to other dihydropyridine calcium channel blockers, with minimal negative inotropic effects on the myocardium at therapeutic doses. Its high lipophilicity gives lercanidipine a gradual onset of action and a prolonged duration of effect, allowing once-daily dosing while minimizing reflex tachycardia. The vasodilation produced by lercanidipine occurs predominantly in resistance arterioles, reducing afterload on the left ventricle and lowering both systolic and diastolic blood pressure. The antihypertensive effect is dose-dependent and sustained over 24 hours with once-daily administration.

Therapeutic Uses

Lercanidipine Hydrochloride is indicated for the management of:

• Essential Hypertension: First-line treatment for mild to moderate essential hypertension as monotherapy or in combination with other antihypertensive agents such as ACE inhibitors, angiotensin II receptor blockers, or beta-blockers.
• Isolated Systolic Hypertension: Effective in reducing systolic blood pressure in elderly patients with isolated systolic hypertension.
• Chronic Stable Angina: Provides antianginal benefit through coronary vasodilation and reduction of myocardial oxygen demand via afterload reduction.

Why Manufacturers Choose Lercanidipine Hydrochloride

Lercanidipine hydrochloride offers a valuable opportunity for Indian pharmaceutical manufacturers to expand their antihypertensive portfolio with a newer-generation calcium channel blocker that is well-tolerated and has lower incidence of ankle edema compared to amlodipine. The molecule is included in major pharmacopoeias including IP, BP, and USP, providing clear regulatory pathways for domestic and export markets. Its once-daily dosing and favorable side effect profile make it attractive for PCD franchise networks targeting cardiologists and general physicians. Indian manufacturers can leverage existing tablet manufacturing infrastructure to produce lercanidipine hydrochloride tablets at competitive prices, particularly for the Middle East, Southeast Asian, and African export markets.